Use of serum uPA change to predict PFS and overall survival in first-line trastuzumab-treated breast cancer

被引：0
|
作者：
Hou, H. Y.
Anyanwu, U.
Jamshidi, N.
Leitzel, K.
Ali, S. M.
Koestler, W.
Fuchs, E.
Hamer, P.
Carney, W. P.
Lipton, A.
机构：
[1] Penn State Hershey Med Ctr, Hershey, PA USA
[2] Lebanon VA Med Ctr, Lebanon, PA USA
[3] Med Univ Vienna, Vienna, Austria
[4] Siemens Healthcare Diagnost, Cambridge, MA USA
来源：
JOURNAL OF CLINICAL ONCOLOGY | 2010年 / 28卷 / 15期
关键词：
D O I：
10.1200/jco.2010.28.15_suppl.1050
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
1050
引用
收藏
页数：1
相关论文
共 50 条
  • [31] Use of bevacizumab as a first-line treatment for metastatic breast cancer
    Manso, L.
    Moreno, F.
    Marquez, R.
    Castelo, B.
    Arcediano, A.
    Arroyo, M.
    Ballesteros, A. I.
    Calvo, I.
    Echarri, M. J.
    Enrech, S.
    Gomez, A.
    Gonzalez del Val, R.
    Lopez-Miranda, E.
    Martin-Angulo, M.
    Martinez-Janez, N.
    Olier, C.
    Zamora, P.
    CURRENT ONCOLOGY, 2015, 22 (02) : E51 - E60
  • [32] Early onset hypothyroidism as a predictor for progression-free survival (PFS) and overall survival (OS) benefit in patients with advanced renal cell carcinoma treated with first-line sunitinib
    Pinto, Alvaro
    Garrido, Maria
    Cruz, Patricia
    Lopez, David
    Zambrana, Francisco
    Aguayo, Cristina
    Fellu, Jaime
    Espinosa, Enrique
    JOURNAL OF CLINICAL ONCOLOGY, 2014, 32 (15)
  • [33] Time trends in overall survival (OS) and progression-free survival (PFS) in the first-line treatment of advanced non-small-cell lung cancer (NSCLC).
    Rutkowski, Jacek
    Saad, Everardo D.
    Buyse, Marc E.
    Jassem, Jacek
    JOURNAL OF CLINICAL ONCOLOGY, 2016, 34 (15)
  • [34] Addition of Capecitabine in Breast Cancer First-line Chemotherapy Improves Survival of Breast Cancer Patients
    Xu, Di
    Chen, Xiu
    Li, Xingjiang
    Mao, Zhixiang
    Tang, Wenjuan
    Zhang, Wei
    Ding, Li
    Tang, Jinhai
    JOURNAL OF CANCER, 2019, 10 (02): : 418 - 429
  • [35] Bevacizumab and taxanes in the first-line treatment of metastatic breast cancer : overall survival and subgroup analyses of the ATHENA study in France
    Pierga, Jean-Yves
    Delva, Remy
    Pivot, Xavier
    Espie, Marc
    Dalenc, Florence
    Serin, Daniel
    Veyret, Corinne
    Lortholary, Alain
    Gligorov, Joseph
    Joly, Katelle
    Hernandez, Juana
    Hardy-Bessard, Anne-Claire
    BULLETIN DU CANCER, 2014, 101 (09) : 780 - 788
  • [36] Long-term outcome of HER2 positive metastatic breast cancer patients treated with first-line trastuzumab
    Yeo, B.
    Kotsori, K.
    Mohammed, K.
    Walsh, G.
    Smith, I. E.
    BREAST, 2015, 24 (06): : 751 - 757
  • [37] Progression-free survival as a surrogate for overall survival in first-line chemotherapy for advanced pancreatic cancer
    Hamada, Tsuyoshi
    Nakai, Yousuke
    Isayama, Hiroyuki
    Yasunaga, Hideo
    Matsui, Hiroki
    Takahara, Naminatsu
    Mizuno, Suguru
    Kogure, Hirofumi
    Matsubara, Saburo
    Yamamoto, Natsuyo
    Tada, Minoru
    Koike, Kazuhiko
    EUROPEAN JOURNAL OF CANCER, 2016, 65 : 11 - 20
  • [38] Cardiotoxicity manifestations in metastatic breast cancer patients treated with trastuzumab as first line.
    Sherman, Shira
    Barkan, Tamar
    Yerushalmi, Rinat
    JOURNAL OF CLINICAL ONCOLOGY, 2020, 38 (15)
  • [39] The use of myocardial deformation imaging to predict cardio toxicity in breast cancer treated with trastuzumab
    Charfeddine, S.
    Yousfi, C.
    Abid, L.
    Abid, D.
    Kammoun, S.
    Ben Kridis, W.
    Sghaier, S.
    Frikha, M.
    EUROPEAN JOURNAL OF HEART FAILURE, 2018, 20 : 406 - 406
  • [40] Trastuzumab as first-line therapy in HER2-positive metastatic breast cancer patients
    Del Mastro, Lucia
    Lambertini, Matteo
    Bighin, Claudia
    Levaggi, Alessia
    D'Alonzo, Alessia
    Giraudi, Sara
    Pronzato, Paolo
    EXPERT REVIEW OF ANTICANCER THERAPY, 2012, 12 (11) : 1391 - 1405
12345